Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel monoclonal antibodies to treat severe autoimmune and inflammatory diseases. The company leverages advanced antibody engineering technologies to create next-generation complement therapeutics with improved selectivity and potency. Its lead program, DNTH103, is a monoclonal antibody targeting the classical complement pathway for conditions such as generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. Based in New York City and Waltham, Massachusetts, Dianthus aims to deliver transformative medicinal therapies by addressing unmet needs in autoimmune treatment.
2 - 10 employees
Founded 2017
𧬠Biotechnology
π Pharmaceuticals
π° $100M Private Equity Round on 2022-04
5 days ago
Lead device design and development for novel drug delivery systems as part of Dianthus Therapeutics.
December 21, 2024
Join Dianthus Therapeutics as an Accounts Payable and Payroll Manager. Responsible for payroll processing and accounts payable operations.
πΊπΈ United States β Remote
π° $100M Private Equity Round on 2022-04
β° Full Time
π Senior
π΄ Lead
π§βπ« Bookkeeping and Clerks
December 12, 2024
Oversee clinical data management responsibilities in a biotech company focused on antibody therapeutics.
πΊπΈ United States β Remote
π° $100M Private Equity Round on 2022-04
β° Full Time
π Senior
π Data Scientist
December 7, 2024
Lead clinical operations for global trials at Dianthus Therapeutics. Oversee strategy, efficient planning, and execution.
π Anywhere in the World β Remote
π° $100M Private Equity Round on 2022-04
β° Full Time
π΄ Lead
βοΈ Operations
November 28, 2024
Dianthus Therapeutics seeks a clinical director to lead phase III trials for autoimmune therapies. This remote role involves oversight of medical monitoring and driving clinical strategy.
πΊπΈ United States β Remote
π° $100M Private Equity Round on 2022-04
β° Full Time
π Senior
π Director
October 4, 2024
Leads medical affairs strategy for European market at Dianthus Therapeutics.
πͺπΊ Anywhere in Europe β Remote
π° $100M Private Equity Round on 2022-04
β° Full Time
π Senior
π Director